U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07531745) titled 'ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome' on April 08.
Brief Summary: The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Dravet Syndrome
Intervention:
DRUG: ION337
ION337 will be administered by ITB injection.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Ionis Pharmaceuticals, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....